B of A Securities Maintains Underperform on Sutro Biopharma, Lowers Price Target to $0.8

+0.57%

Sutro Biopharma

STRO

0.00

B of A Securities analyst Tazeen Ahmad maintains Sutro Biopharma (NASDAQ: STRO) with a Underperform and lowers the price target from $1 to $0.8.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Assessing AbbVie’s Share Value After Stock Climbs 31.7% in 2025

What ANI Pharmaceuticals (ANIP)'s Rare Disease Revenue Surge Means for Shareholders

Enlivex Therapeutics Ltd. Announces Six-Month Efficacy Data From Phase IIa Allocetra Trial in Knee Osteoarthritis Patients Aged 60+

BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

AbbVie to Participate in Piper Sandler 37th Annual Healthcare Conference

Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $14

Truist Securities Initiates Coverage On Bicycle Therapeutics with Hold Rating, Announces Price Target of $10

What's Driving the Market Sentiment Around ADMA Biologics Inc?